Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2024 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
GRCE on Nasdaq
Shares outstanding
14,054,374
Price per share
$3.17
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
3,706,227
Total reported value
$11,033,102
% of total 13F portfolios
0%
Share change
-110,681
Value change
-$328,366
Number of holders
20
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nantahala Capital Management, LLC 10% 0% $4,198,056 +$36,654 1,404,032 +0.88% Nantahala Capital Management, LLC 30 Jun 2025
HIRSCHMAN ORIN 9.9% +96% $2,446,401 +$1,482,398 1,322,379 +154% HIRSCHMAN ORIN 31 Mar 2025

As of 30 Sep 2025, 20 institutional investors reported holding 3,706,227 shares of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE). This represents 26% of the company’s total 14,054,374 outstanding shares.

Top 22 Institutional Shareholders

The largest institutional shareholders of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) together control 26% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Nantahala Capital Management, LLC 8.4% 1,178,203 0% 0.22% $3,511,045
AIGH Capital Management LLC 6.5% 907,217 -20% 0.95% $2,699,127
BANK OF AMERICA CORP /DE/ 3.5% 494,698 0% 0% $1,472,716
VANGUARD GROUP INC 2.9% 409,100 0% 0% $1,215,028
ADAR1 Capital Management, LLC 2.5% 350,450 +98% 0.1% $1,043,290
Stonepine Capital Management, LLC 1.5% 211,010 -28% 0.51% $628,177
RENAISSANCE TECHNOLOGIES LLC 0.6% 84,561 +206% 0% $251,738
CITADEL ADVISORS LLC 0.19% 27,265 -21% 0% $80,977
Millington Financial Advisors, LLC 0.14% 20,000 0% 0.03% $59,700
SeaCrest Wealth Management, LLC 0.1% 14,000 0% $42,042
CITIGROUP INC 0.02% 2,757 +275600% 0% $8,188
NATIONAL BANK OF CANADA /FI/ 0.02% 2,716 0% 0% $8,039
MORGAN STANLEY 0.01% 1,848 0% 0% $5,501
Tower Research Capital LLC (TRC) 0.01% 1,610 +19% 0% $4,793
ROYAL BANK OF CANADA 0% 543 0% 0% $2,000
Activest Wealth Management 0% 104 0% 0% $310
SBI Securities Co., Ltd. 0% 101 0% 0% $301
Steward Partners Investment Advisory, LLC 0% 41 0% 0% $122
NBC SECURITIES, INC. 0% 2 0% $5
Federation des caisses Desjardins du Quebec 0% 1 0% 0% $3
Palumbo Wealth Management LLC 0% 0 -100% $0
JONES FINANCIAL COMPANIES LLLP 0% 0 -100% $0

Institutional Holders of Grace Therapeutics, Inc. - Common Stock, par value $0.0001 per share (GRCE) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 0 $0 -$42,042 $3.17 0
2025 Q3 3,706,227 $11,033,102 -$328,366 $2.98 20
2025 Q2 3,816,908 $11,344,205 -$607,725 $2.97 20
2025 Q1 4,024,092 $9,168,718 +$4,408,642 $2.28 17
2024 Q4 2,087,877 $7,835,456 +$4,246,555 $3.74 15
2024 Q3 959,571 $2,878,713 +$2,878,713 $3.00 1